Buy Methylallyltryptamine (MALT) Cas 1366416-29-6

Buy Methylallyltryptamine (MALT) Cas 1366416-29-6

Methylallyltryptamine (MALT), also known as N-methyl-N-allyltryptamine, is a lesser-known psychedelic drug from the tryptamine family.^[1] It is a novel compound with very little history of human use.^[1] It is closely related to methylpropyltryptamine (MPT).^[1] The drug has been sold online as a designer drug.^[1] Very little information on the pharmacology or toxicity of MALT is available.^{[citation needed]}

MALT was not included in Alexander Shulgin‘s 1997 book TiHKAL (Tryptamines I Have Known and Loved).^[2] However, years after the book’s publication, he described MALT as having important unexplored potential as a psychedelic drug.^[3] Subsequently, MALT was encountered as a novel designer drug.^[1] It has been reported to have been used at doses of 25 to 50 mg via routes including oral, smoking, or vaping.^[1] The drug’s effects have been described as comparable to those of methylpropyltryptamine (MPT) but less pronounced.^[1]

MALT is a serotonin receptor modulator and has been found to interact with the serotonin 5-HT_1A, 5-HT_2A, and 5-HT_2C receptors.^[4]

Analogues of MALT include 4-HO-MALT, 4-AcO-MALT, 5-MeO-MALT, diallyltryptamine (DALT), methylpropyltryptamine (MPT), and methylisopropyltryptamine (MiPT), among others.

MALT was first described in the scientific literature by Niels Jensen of the University of Göttingen by 2004.^[4] The drug was subsequently first encountered as a novel designer drug by 2018.^[1]

MALT is not explicitly scheduled in any countries; however, it could be considered a psychoactive substance under the United Kingdom Psychoactive Substances Act, which requires the prosecutor to prove that the substance is psychoactive in order for a person to be charged with an offense.^[5] It could also be considered a structural analogue of a scheduled substance under the United States Federal Analogue Act due to its similarity to scheduled tryptamines. It is not a controlled substance in Canada as of 2025.^[6]